The genetics and epigenetics of Neonatal Abstinence Syndrome.
Epigenetics
Genetics
Neonatal Abstinence Syndrome (NAS)
Neonatal Opioid Withdrawal Syndrome (NOWS)
Journal
Seminars in fetal & neonatal medicine
ISSN: 1878-0946
Titre abrégé: Semin Fetal Neonatal Med
Pays: Netherlands
ID NLM: 101240003
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
3
2
2019
medline:
27
11
2019
entrez:
3
2
2019
Statut:
ppublish
Résumé
Neonatal abstinence syndrome (NAS) due to in-utero opioid exposure is a growing epidemic with significant variability in clinical presentation and severity. Currently, NAS severity cannot be predicted based on clinical factors alone. To date, small studies have identified genetic variants in opioid receptor and stress response genes that are associated with differences in NAS pharmacologic treatment rates and length of hospitalization. In addition, epigenetic variation in the mu opioid receptor (OPRM1) gene has been associated with differences in NAS hospitalization outcomes. Examination of maternal genetic and epigenetic profiles may assist in prediction of NAS severity. Large-scale genomic studies are needed to elucidate the genetic architecture of and epigenetic modification related to NAS in order to develop more tailored personalized treatments for NAS.
Identifiants
pubmed: 30709700
pii: S1744-165X(19)30010-1
doi: 10.1016/j.siny.2019.01.002
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Receptors, Opioid, mu
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-110Informations de copyright
© 2019 Elsevier Ltd. All rights reserved.